Regeneron’s Eylea HD Receives FDA Complete Response Letter Despite Priority Review
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received a Complete Response Letter (CRL)...
Ophthalmology
Regeneron’s Eylea HD Receives FDA Priority Review for Macular Edema Treatment
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGNN) announced that the U.S. Food and Drug Administration (FDA) has...
Zhaoke Ophthalmology Enrolls First Patient for Cyclosporine A Eye Gel Phase III Study
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the first patient enrollment in a Phase...
Zhaoke Ophthalmology Signs Distribution Agreements with Thailand’s Interpharma for Myopia and Presbyopia Treatments
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the signing of three distribution and supply...
Zhaoke Ophthalmology Launches Phase II Study for Brimochol PF in Presbyopia Treatment
Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the initiation of a multi-center, double-blinded, crossover, placebo-controlled...
IVIEW Therapeutics’ IVIEW-1201 Gains FDA Orphan Drug Designation for Fungal Keratitis
China-based IVIEW Therapeutics Inc. announced that it has received Orphan Drug Designation (ODD) from the...
Gaush Meditech’s Corneal Confocal Microscope Approved in Jiangsu
Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced that it has received market approval from the...
Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU
German pharmaceutical giant Bayer (ETR: BAYN) announced that it has submitted an indication approval filing...
Santen’s Tapcom Approved by China’s NMPA for Glaucoma Treatment
Japan-based Santen Pharmaceutical Co., Ltd. announced that it has received marketing approval from China’s National...
Alcon Laboratories Acquires Majority Stake in Aurion Biotech to Advance Eye Disease Cell Therapy
US-based eye care firm Alcon Laboratories, Inc. has announced the acquisition of a majority stake...
Formosa Pharmaceuticals Inks Licensing Pact with Cipla for APP13007 in 11 Countries
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with India-headquartered Cipla Limited (BOM: 500087,...
Frontera Therapeutics Receives NMPA Approval for FT-003 in Diabetic Retinopathy Study
Sino-US firm Frontera Therapeutics, Inc. announced receiving approval from China’s National Medical Products Administration (NMPA)...
Innovent Biologics’ Sycume Approved by China’s NMPA for Thyroid Eye Disease
China-based Innovent Biologics Inc. (HKG: 1801) announced that its New Drug Application (NDA) for Sycume...
Gaush Meditech’s ANTERION Ophthalmic Detector Receives NMPA Market Approval
Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced receiving market approval from the National Medical Products...
Gaush Meditech Receives NMPA Approval for Femtosecond Laser Corneal Refractive Surgery System
Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced receiving market approval from the National Medical Products...
TowardPi Medical Secures RMB500 Million in Series E Round for Ophthalmic Equipment Expansion
China-based TowardPi (Beijing) Medical Technology Ltd, a leading ophthalmology equipment R&D company, has reportedly secured...
Sinocelltech Group Receives NMPA Approval for SCTT11 Clinical Study in Thyroid Eye Disease
China-based Sinocelltech Group Ltd (SHA: 688520) has announced receiving approval from the National Medical Products...
Zeiss Group’s VISUMAX 800 with SMILE pro Software Approved by China’s NMPA
Germany-based Zeiss Group, a specialist in optical systems and optoelectronic product manufacturing, announced that it...
Eyebright Medtech Plans Private Placement to Expand Contact Lens Production
China-based Eyebright Medical Technology (Beijing) Co., Ltd. (SHA: 688050), an ophthalmic medical device manufacturer, announced...
Hengrui Pharma’s HR19034 Eye Drops for Myopia Delay Accepted by NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its market filing for HR19034 eye...